Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05630209
Other study ID # BT016
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date January 4, 2023
Est. completion date January 2026

Study information

Verified date November 2023
Source InSightec
Contact Nadir Alikacem
Phone +12146302000
Email nadira@insightec.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type2.0/2.1 in combination with Doxorubicin therapy for the treatment of DIPG in pediatric patients


Description:

This is a prospective, single arm, non-randomized feasibility study to evaluate the safety, feasibility and preliminary efficacy of Blood Brain Barrier Disruption (BBBD) using the Exablate Type 2 system in pediatric patients with Diffuse Intrinsic Pontine Gliomas (DIPG)undergoing Doxorubicin chemotherapy. The study will be conducted at up to three sites in the United States. Patients will undergo 3 treatment cycles, approximately 4 -6 weeks apart. The study aims to establish feasibility and safety of Exablate BBBD in conjunction with Doxorubicin in the treatment of pediatric DIPG and assess preliminary efficacy in this patient population.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date January 2026
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 5 Years to 21 Years
Eligibility Inclusion Criteria: - Age between 5 and 21 years, inclusive - Patient diagnosed with DIPG - At least 4-week and not greater than 12 weeks from completion of radiation therapy - Post-radiation imaging does not show evidence of necrosis/ hemorrhage or other features that contraindicate MRgFUS - If brain surgery occurred, at least 14 days passed since last brain surgery and the patient is fully recovered and neurologically stable - If on steroids, stable or decreasing dose for at least 7 days prior to study entry - Stable or improving neurologic status for 7 days prior to study entry - Able and willing to give consent and/or assent or have a legal guardian who is able and willing to do so - Able to attend all study visits and with life expectancy of at least 6 months Exclusion Criteria: - Tumor not visible on any pre-therapy or post-radiation imaging - Previous participation in other chemotherapy, molecularly targeted therapy, or immunotherapy treatment-related phase 1 or 2 trials - Symptoms and signs of increased intracranial pressure - Subject with metastatic disease - Subject with ventricular peritoneal shunt - Subject receiving bevacizumab (Avastin) therapy or increasing doses of steroids - Anti-coagulant therapy, or medications known to increase risk of hemorrhage, (e.g., ASA, non-steroidal anti-inflammatory drugs [NSAIDs], statins) within washout period prior to treatment - History of a bleeding disorder, coagulopathy or with a history of spontaneous tumor hemorrhage. - Hypertension per age - Cerebral or systemic vasculopathy, including intracranial thrombosis, vascular malformation, cerebral aneurysm, or vasculitis - Immunosuppression (corticosteroids to prevent/treat brain edema are permitted). - Patients with positive HIV status - Active seizure disorder or epilepsy (seizures despite medical treatment) for a minimum of 4 weeks prior to first cycle/Exablate BBBD procedure captured by history - Known sensitivity to gadolinium-based contrast agents - Known sensitivity to DEFINITY® ultrasound contrast agent or known hypersensitivity to perflutren microsphere or its components, e.g., polyethylene glycol - Contraindication to Doxorubicin - Previous treatment with complete cumulative doses of Doxorubicin, daunorubicin, idarubicin, and/or other anthracyclines and anthracenediones - Severely impaired renal function with estimated glomerular filtration rate <2 standard deviations for age - Patients that may require trastuzumab during the study - Patients that may require inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp during the study

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Exablate
Blood Brain Barrier Disruption (BBBD) via Exablate Type 2 system with microbubble resonators on the day of Doxorubicin infusion to treat DIPG brain tumors
Drug:
Doxorubicin
Doxorubicin infusion

Locations

Country Name City State
United States Nicklaus Children's Hospital Miami Florida
United States Children's National Medical Center Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
InSightec

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Progression Free Survival (PFS) PFS will be assessed based on the Response Assessment in Pediatric Neuro-Oncology (RAPNO) scale. 2 years
Primary Adverse Events All adverse events from first treatment to end of study will be documented and reported according to the CTCAE terminology and severity scale 2 years
Secondary Blood Brain Barrier Disruption (BBBD) BBBD will be assessed as a comparative ratio measured in pre and post-sonication contrast-enhanced MR images immediately post BBBD sonication
See also
  Status Clinical Trial Phase
Recruiting NCT05023434 - A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors
Completed NCT04474678 - Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!") N/A
Completed NCT02768389 - Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma Early Phase 1
Terminated NCT01902771 - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT03286335 - Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy N/A
Recruiting NCT05968053 - Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
Recruiting NCT05358340 - Dual Perfusion Imaging for Characterizing Vascular Architecture of Brain Lesions N/A
Recruiting NCT03276676 - [18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors Phase 2
Completed NCT02851355 - Follow-up Survey of Patients Who Were Treated for Medulloblastoma or Primitive Neuroectodermal Tumors of the Central Nervous in Norway
Completed NCT02409121 - A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers N/A
Completed NCT02558569 - The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block Phase 4
Completed NCT02713087 - Vasopressor Effects in Anesthetized Patients Phase 4
Terminated NCT02674945 - Understanding and Improving Quality of Life Through a Wireless Activity Tracker: Observational Phase
Withdrawn NCT02165995 - Use of Navigated Transcranial Magnetic Stimulation (nTMS) in Generated Motor and Language Mapping to Evaluate Brain Recovery Following Surgery N/A
Withdrawn NCT01202539 - Real-time Assessment of Frameless Intrafraction Motion
Completed NCT01171469 - Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor Phase 1
Terminated NCT01044966 - A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma Phase 1/Phase 2
Completed NCT00760409 - Differentiating Recurrent Brain Tumor Versus Radiation Injury Using MRI N/A
Completed NCT00503204 - Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour Phase 1